Article
Liquid biopsy in clinical outcomes and detection of T790M mutation in metastatic non-small cell lung cancer after progression to EGFR-TKI.
Cancer biomarkers : section A of Disease markers - 1 Jan 2025
Heredia David, Bolaño-Guerra Laura, Valencia-Velarde Angel, Santoyo Edgar Varela, Lara-Mejía Luis, Cárdenas-Fernández Daniela, Orozco Mario, Cruz-Rico Graciela, Arrieta Oscar
Abstract excerpt
BACKGROUNDLiquid biopsy (LB) is used to detect epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) and has been demonstrated to have prognostic and predictive value.OBJECTIVETo associate the rates of EGFR and T790M mutations detected by LB during disease progression after first- or second-generation EGFR-TKIs with clinical characteristics and survival outcomes.METHODSFrom...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
